UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
Cambridge, MA | ||
(Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code): (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.07 | Submission of Matters to a Vote of Security Holders. |
On June 11, 2021, Mersana Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the stockholders of the Company voted on four proposals as follows: (i) to elect Willard Dere, M.D., and Martin Huber, M.D., each as a Class I member of the board of directors to serve until the Company’s 2024 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal (“Proposal 1”); (ii) to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 (“Proposal 2”); (iii) to approve, on an advisory basis, the compensation of the Company’s named executive officers (“Proposal 3”); and (iv) to approve, on an advisory basis, the holding of an annual say-on-pay vote on executive compensation (“Proposal 4”).
The Company’s stockholders approved Proposal 1. The votes cast at the Annual Meeting were as follows:
Nominee | Votes For | Withheld | Broker Non-Votes | |||||||||
Willard Dere, M.D. | 47,965,088 | 11,208,450 | 3,408,118 | |||||||||
Martin Huber, M.D. | 48,339,079 | 10,834,459 | 3,408,118 |
The Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows:
Votes For | Votes Against | Abstain | ||||||||
62,433,551 | 141,363 | 6,742 |
The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows:
Votes For | Votes Against | Abstain | ||||||||
56,298,403 | 2,858,423 | 16,712 |
The Company’s stockholders approved Proposal 4. The votes cast at the Annual Meeting were as follows:
1 Year | 2 Years | 3 Years | Abstain | |||||||||||
58,987,861 | 756 | 172,533 | 12,388 |
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | Description | |
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MERSANA THERAPEUTICS, INC. | ||
By: | /s/ Brian DeSchuytner | |
Brian DeSchuytner | ||
Senior Vice President, Finance & Product Strategy |
Date: June 17, 2021